about
A gain-of-function mutation in adenylate cyclase 3 protects mice from diet-induced obesityFGF21 promotes metabolic homeostasis via white adipose and leptin in miceA volumetric method for quantifying atherosclerosis in mice by using microCT: comparison to en faceAntidiabetic effects of glucokinase regulatory protein small-molecule disruptorsSmall molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-conceptSmall molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profilesSmall molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine seriesSmall molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocketSmall Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational AnalysisIdentification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in miceA mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in miceNew variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification.A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.SUN1 interacts with nuclear lamin A and cytoplasmic nesprins to provide a physical connection between the nuclear lamina and the cytoskeletonExpression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts.Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistanceMolecular targeting of the GK-GKRP pathway in diabetes.Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes.Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational Constraint.Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophyLessons from lipodystrophy:LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophyAnti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
P50
Q27335317-4CD218E9-EC46-4D9E-B866-A2B07393A354Q27335466-6F072954-3778-4EAC-9628-D8F6CCF25B4FQ27347208-8379DC2A-E241-46F4-A623-7323041AE1DEQ27687521-A182A0EB-4FB1-4E39-B2DB-9A5ED4104457Q27688112-8976570C-7B1E-4F71-9E61-8226249094E5Q27688116-32AE2378-BCD0-4E30-A288-30E33E9A2DCCQ27689457-F6A742CB-5690-4088-B003-9564586C77C2Q27694487-3948161D-762B-4F1E-94E5-19D232A0FF34Q27700256-1F0FBFC8-7405-4179-AFA8-39BAE2E03DB4Q28588894-7519E4C1-BB18-45DB-9470-BDFA6A8756A4Q28592410-CFCD84EF-1093-4842-AB9C-74CA638A9979Q33439944-64AF2CB6-9BAA-4033-8955-8B84E3F2201FQ33604576-8886EC80-115C-4ECB-BAD7-62A975CA5B92Q34717324-25D17903-EA23-4718-AD49-5095DBF2AA13Q37093107-A63695A4-D423-4841-981C-4FC10093A78EQ37163525-E45E5B28-D8FB-43F5-99ED-DFE82EBB09F9Q38260964-D94CB1D0-0823-4FAB-977B-E346296957DDQ38294962-0642630D-2C55-4C69-A31E-461ADCEAC7ACQ38794917-BDBD6251-8278-47F2-B9BE-F5CE27F5D263Q43224118-6ECE43EF-216A-4AB6-9978-0B10C572ACB6Q45968669-C71A2B49-82E5-4170-A464-E2E208ABF0FBQ46227298-279D003E-DC21-4160-BD6F-01D82A84CC4EQ46268292-8B62EA97-1842-4C2C-AF68-2A66F1226860Q53514538-BC9FD253-C7FE-4171-85DC-A6B8A239262AQ54064162-4EF18259-8624-4A68-BCDF-5F7FC323AC53Q57149453-6FAA7EC0-CE28-4251-8DFF-BCEE67641485Q57149483-2866F061-3D24-4683-BFAF-A58630EADDC2Q90645845-9AE6FF1E-7C73-4455-BCA0-FD54B697866B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David J Lloyd
@ast
David J Lloyd
@en
David J Lloyd
@es
David J Lloyd
@nl
type
label
David J Lloyd
@ast
David J Lloyd
@en
David J Lloyd
@es
David J Lloyd
@nl
prefLabel
David J Lloyd
@ast
David J Lloyd
@en
David J Lloyd
@es
David J Lloyd
@nl
P106
P108
P21
P31
P496
0000-0001-5924-0672